Abstract:Purpose(:) To evaluate the pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in diagnosing and staging liver fibrosis in rabbits.Materials and Methods: DCE-MRI with gadodiamide (Gd-DTPA-BMA) was performed on a 3.0 Tesla, 60cm bore MR scanner for rabbits with CCl4-induced liver fibrosis, and an untreated control group. Fibrosis was staged according to the METAVIR system: control (F0; n=13), nonadvanced fibrosis (F1-2; n=15), and advanced fibrosis (F3-4; n=12). The DCE-MRI parameters K-trans, k(ep), V-e, and v(p) were measured with a dual-input extended Tofts model. Receiver operating characteristic analyses were performed to assess the diagnostic performance of K-trans, V-e, and v(p) in staging liver fibrosis.Results: Both K-trans and V-e decreased with increasing fibrosis stage. K-trans of the control group was significantly different from that of the overall fibrosis group, nonadvanced group, and advanced group (P < 0.001 for all). Significant differences were found between V-e of the control group and that of the overall fibrosis and advanced groups (P=0.019 and P=0.009, respectively). For K-trans, the areas under the receiver operating characteristic curve (AUROCs) for discriminating the control group from the overall fibrosis and advanced fibrosis groups were 0.909 (95% confidence interval [CI], 0.809-1.000), and 0.936 (95% CI, 0.847-1.000), respectively. For discriminating between the control and nonadvanced fibrosis groups, the AUROC of K-trans was 0.887 (95% CI, 0.762-1.000). The AUROCs of K-trans were higher than those of V-e and v(p) for discriminating between the control and overall fibrosis groups, the control and nonadvanced fibrosis groups, and the control and advanced fibrosis groups. Pharmacokinetic parameters were negatively correlated with fibrosis stage (K-trans, rho=-0.668, P < 0.001; V-e, rho=-0.438, P=0.005; v(p), rho=-0.360, P=0.023).Conclusion: Among pharmacokinetic parameters of DCE-MRI in our study, K-trans was an excellent predictor for differentiating fibrotic livers from normal livers, and differentiating normal livers from nonadvanced or advanced fibrosis livers.

Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat

Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model.

Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model

Molecular Magnetic Resonance Imaging of Activated Hepatic Stellate Cells with Ultrasmall Superparamagnetic Iron Oxide Targeting Integrin αvβ3 for Staging Liver Fibrosis in Rat Model

Integrin-Targeted Theranostic Nanoparticles for Clinical MRI-Traceable Treatment of Liver Fibrosis

Molecular Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin Αvβ3 Expression with SPECT in Rat

Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin Αvβ3-Targeting Radiotracer.

T 1-T2 Dual-Modal Magnetic Resonance Contrast-Enhanced Imaging for Rat Liver Fibrosis Stage

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Efficacy of Ultrasound Microbubble-HGF Complex for Treating Hepatic Fibrosis and Its Relation with Perfusion Weighted Imaging

Non-invasively Differentiate Non-Alcoholic Steatohepatitis by Visualizing Hepatic Integrin Αvβ3 Expression with a Targeted Molecular Imaging Modality

MR Imaging of Activated Hepatic Stellate Cells in Liver Injured by CCl 4 of Rats with Integrin-Targeted Ultrasmall Superparamagnetic Iron Oxide

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Non-invasively Differentiating Extent of Liver Fibrosis by Visualizing Hepatic Integrin Αvβ3 Expression with an MRI Modality in Mice

Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles

Staging of Liver Fibrosis Treated with Hepatocyte Growth Factor by Ultrasound Cationic Microbubble Nano-Liposomes Using 1H Magnetic Resonance Spectroscopy

Efficacy of HGF Carried by Ultrasound Microbubble-Cationic Nano-Liposomes Complex for Treating Hepatic Fibrosis in a Bile Duct Ligation Rat Model, and Its Relationship with the Diffusion-Weighted MRI Parameters.

Integrin receptor targeted cRGD-conjugated magnetic nanoparticles forvitro imaging experimental hepatic cancer cells

Enhanced Ferritin‐Manganese Interaction by Nanoplatinum Growth Enabling Liver Fibrosis 3D Magnetic Resonance Visualization and Synergistic Therapy with Real‐Time Monitoring

Assessment and integration of multiparametric MRI for liver fibrosis staging in rat non-alcoholic steatohepatitis: Evaluation of diagnostic efficiency and model interpretation

Collagen-Targeting Self-Assembled Nanoprobes for Multimodal Molecular Imaging and Quantification of Myocardial Fibrosis in a Rat Model of Myocardial Infarction